产品说明书

Enrofloxacin

Print
Chemical Structure| 93106-60-6 同义名 : BAY Vp 2674;PD160788;endrofloxicin.;CFPQ;Enrofloxacine;Baytril;ENR
CAS号 : 93106-60-6
货号 : A127543
分子式 : C19H22FN3O3
纯度 : 98+%
分子量 : 359.395
MDL号 : MFCD00792463
存储条件：

粉末 Inert atmosphere,Room Temperature

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 9 mg/mL(25.04 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 1 mg/mL(2.78 mM)，配合低频超声，并水浴加热至45℃助溶
动物实验配方：
生物活性
描述 Enrofloxacin (EF) is an extensively used animal-specific antibacterial agent that leaves drug residues in the environment[3]. The in vivo effectiveness of enrofloxacin against E. coli in different organs varied, with the Emax ranging from - 4.4 to - 5.8 Log10 colony forming units (cfu)/mL or cfu/g. The AUC0-24/MIC ratio of the combination of enrofloxacin and ciprofloxacin producing bactericidal and elimination effects were 21.29 and 32.13 in blood; 41.68, and 58.52 in the liver; and 27.65 and 46.22 in the lung, respectively[4]. The most effective antibiotics tested in vitro were fluoroquinolones (MIC90 danofloxacin 0.312 μg/mL, enrofloxacin 0.312 μg/mL, marbofloxacin 0.625 μg/mL)[5]. Enrofloxacin reduced C. jejuni cell densities within the cecal and colonic digesta for all treatments, and densities shed in feces as a function of antibiotic duration[6].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03575312 Healthy Not Applicable Completed - Germany ... 展开 >> Fraunhofer Institute for Toxicology and Experimental Medicine Hannover, Germany, 30625 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.78mL

0.56mL

0.28mL

13.91mL

2.78mL

1.39mL

27.82mL

5.56mL

2.78mL
参考文献

[1]Kung K, Riond JL, Wanner M. Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intravenous and oral administration of enrofloxacin in dogs. J Vet Pharmacol Ther. 1993 Dec;16(4):462-8.

[2]Prescott JF, Yielding KM. In vitro susceptibility of selected veterinary bacterial pathogens to ciprofloxacin, enrofloxacin and norfloxacin. Can J Vet Res. 1990 Jan;54(1):195-7.

[3]Lu X, Li Y, Thunders M, et al. Effect of enrofloxacin on the proteome of earthworms. Sci Total Environ. 2018;616-617:531–542

[4]Xiao X, Jiang L, Lan W, Jiang Y, Wang Z. in vivo pharmacokinetic/Pharmacodynamic modeling of Enrofloxacin against Escherichia coli in broiler chickens. BMC Vet Res. 2018;14(1):374.

[5]Sulyok KM, Kreizinger Z, Fekete L, et al. Antibiotic susceptibility profiles of Mycoplasma bovis strains isolated from cattle in Hungary, Central Europe. BMC Vet Res. 2014;10:256.

[6]Inglis GD, Zaytsoff SJM, Selinger LB, Taboada EN, Uwiera RRE. Therapeutic administration of enrofloxacin in mice does not select for fluoroquinolone resistance in Campylobacter jejuni. Can J Microbiol. 2018;64(10):681–694